Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 5/100

Termination Rate

0.0%

0 terminated out of 23 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

57%

13 trials in Phase 3/4

Results Transparency

69%

9 of 13 completed with results

Key Signals

9 with results100% success

Data Visualizations

Phase Distribution

23Total
P 1 (1)
P 2 (9)
P 3 (13)

Trial Status

Completed13
Recruiting3
Active Not Recruiting3
Withdrawn2
Not Yet Recruiting1
Unknown1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 13 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07269210Phase 2RecruitingPrimary

A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia

NCT06880770Phase 3RecruitingPrimary

Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

NCT07604974Phase 2Recruiting

A Study to Assess the Safety, Tolerability and Efficacy of ION775

NCT06347016Phase 3Active Not RecruitingPrimary

Study of Plozasiran in Adults With Severe Hypertriglyceridemia

NCT06347003Phase 3Active Not RecruitingPrimary

Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

NCT05852431Phase 3CompletedPrimary

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

NCT07680829Phase 3Not Yet RecruitingPrimary

A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia

NCT05355402Phase 2Completed

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Adults With Hypertriglyceridemia and Atherosclerotic Cardiovascular Disease (Established or at Increased Risk for), and/or With Severe Hypertriglyceridemia

NCT04720534Phase 2CompletedPrimary

Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

NCT05079919Phase 3CompletedPrimary

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia

NCT06555640Phase 2CompletedPrimary

A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia

NCT05681351Phase 3Active Not RecruitingPrimary

CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)

NCT05552326Phase 3CompletedPrimary

A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia

NCT04541186Phase 2CompletedPrimary

Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia

NCT03001817Phase 3CompletedPrimary

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function

NCT03011450Phase 3CompletedPrimary

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT04662528Phase 3WithdrawnPrimary

Safety and Efficacy of MAT9001(Omega-3-pentaenoic Acid) in Subjects With Triglycerides ≥500 mg/dL and <2000 mg/dL

NCT02944383Phase 2CompletedPrimary

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

NCT01997268Phase 3WithdrawnPrimary

The Efficacy of EPA+DHA (SC401B) for Lowering Triglyceride Levels (≥ 500 mg/dL)

NCT01242527Phase 2CompletedPrimary

Epanova® for Lowering Very High Triglycerides

Scroll to load more

Research Network

Activity Timeline